Pictet & Cie (Europe) Sa Alnylam Pharmaceuticals, Inc. Transaction History

Pictet & Cie (Europe) Sa

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 07, 2024	BUY	$146.51 - $198.2 $122,335 - $165,497	835 Added 48.35%	2,562 $382,000
Q4 2023 Feb 09, 2024	SELL	$151.41 - $196.57 $9,538 - $12,383	-63 Reduced 3.52%	1,727 $330,000
Q3 2023 Nov 02, 2023	SELL	$170.77 - $211.65 $3,927 - $4,867	-23 Reduced 1.27%	1,790 $317,000
Q2 2023 Aug 08, 2023	BUY	$185.01 - $212.05 $335,423 - $384,446	1,813 New	1,813 $344,000

644

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $28.8B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Pictet & Cie (Europe) Sa, based on Form 13F filings with the SEC.

Stay updated on Pictet & Cie (Europe) Sa with notifications on news.